Intramural Administration of Translational Inhibitor Puromycin Upon Balloon Angioplasty Inhibits SMC Proliferation and Protein Synthesis–Vascular Proteome Profiling Analysis
PROTEOMICS – Clinical Applications · 2025
DOI: 10.1002/prca.202400066 ↗Kurz gefasst
Fachartikel in der Zeitschrift PROTEOMICS – Clinical Applications, 2025. Verfasst von Priyanka Boettger und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine II Cardiology, Intensive Care Medicine, Angiology, St. Marien Hospital, Siegen, Germany. Hauptthemen laut MEDLINE: Puromycin, Myocytes, Smooth Muscle, Proteome, Protein Biosynthesis. Die Arbeit nennt 31 Literaturangaben.
Abstract (Originalsprache)
Introduction
Percutaneous transluminal coronary angioplasty (PTCA) is an effective procedure to decrease the severity of stenotic coronary atherosclerotic lesions. However, its long‐term success is limited by the formation of restenosis or neointima by increased proliferation of smooth muscle cells (SMCs) and synthesis of extracellular matrix. Polypeptide growth factors are potent SMC mitogens and are involved in SMC proliferation and extracellular matrix (ECM) synthesis. In this line, inhibition of de novo protein synthesis might be beneficial.
Methods
We examined the effects of different concentrations of translational inhibitor puromycin on SMC proliferation and apoptosis, in vitro. Further, we examined the effects of local administration of puromycin in a rabbit balloon injury model of the iliac artery.
Results
Injection of puromycin or its vehicle was performed with an infusion‐balloon catheter directly into the vessel wall during angioplasty. PTA in the vehicle group resulted in neointima formation 3 weeks after the vascular intervention. In contrast, puromycin treatment resulted in a significant reduction of intima–media ratio. We observed decreased elastin and collagen III synthesis in puromycin‐treated animals. With proteomics, we could demonstrate reduced protein expression of lamin, vimentin, alpha‐1 antitrypsin, alpha‐actin allowing puromycin treatment. In in vitro experiments, puromycin decreased SMCs proliferation (i.e., BrdU incorporation) following FCS stimulation. Perspective Based on the data from our animal experiments, aministration of puromycin directly into the vessel wall during angioplasty may be effective in preventing or reducing restenosis in humans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine II Cardiology, Intensive Care Medicine, Angiology, St. Marien Hospital, Siegen, Germany.
- Department of Medicine III Martin-Luther-University Halle-Wittenberg, Halle/Saale, Germany.
- Molecular Medicine Program The University of Utah, Salt Lake City, Utah, USA.
- Division of Occupational Medicine, The University of Utah, Salt Lake City, Utah, USA.
- Department of Occupational Medicine, Billings Clinic Bozeman, Bozeman, Montana, USA.
- BASF SE, Ludwigshafen, Germany.
ORCID-Profile: Priyanka Boettger, Michael Buerke
Zitieren
APA
Boettger, P., Schwertz, H., Platsch, H., Mueller-Werdan, U., Werdan, K., & Buerke, M. (2025). Intramural Administration of Translational Inhibitor Puromycin Upon Balloon Angioplasty Inhibits SMC Proliferation and Protein Synthesis–Vascular Proteome Profiling Analysis. PROTEOMICS – Clinical Applications. https://doi.org/10.1002/prca.202400066
Vancouver
Boettger P, Schwertz H, Platsch H, Mueller-Werdan U, Werdan K, Buerke M. Intramural Administration of Translational Inhibitor Puromycin Upon Balloon Angioplasty Inhibits SMC Proliferation and Protein Synthesis–Vascular Proteome Profiling Analysis. PROTEOMICS – Clinical Applications. 2025. doi:10.1002/prca.202400066
BibTeX
@article{Boettger2025,
author = {Boettger, Priyanka and Schwertz, Hansjörg and Platsch, Herbert and Mueller-Werdan, Ursula and Werdan, Karl and Buerke, Michael},
title = {Intramural Administration of Translational Inhibitor Puromycin Upon Balloon Angioplasty Inhibits SMC Proliferation and Protein Synthesis–Vascular Proteome Profiling Analysis},
journal = {PROTEOMICS – Clinical Applications},
year = {2025},
doi = {10.1002/prca.202400066}
}
EUVIMED